Echinocandins: Role in antifungal therapy, 2005

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 10, 2005, Pages 1657-1668

  Zaas, Aimee K ^a   Alexander, Barbara D ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antifungal; Aspergillus; Candida; Echinocandin

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; PYRROLE DERIVATIVE; RAPAMYCIN; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG STRUCTURE; FEBRILE NEUTROPENIA; FUNGUS ISOLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; INCIDENCE; INTENSIVE CARE UNIT; LIVER DISEASE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; NEWBORN INFECTION; NONHUMAN; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SURVIVAL RATE; THRUSH; TREATMENT FAILURE;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; FUNGAL PROTEINS; HUMANS; MYCOSES; PEPTIDES, CYCLIC;

EID: 23844465659     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.10.1657     Document Type: Review

References (69)

1. LETSCHER-BRU V, HERBRECHT R: Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. (2003) 51:513-521.
2. NYFELER R, KELLER-SCHIERLEIN W: [Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components]. Helv. Chim. Acta (1974) 57:2459-2477.
3. MASUREKAR PS, FOUNTOULAKIS JM, HALLADA TC et al.: Pneumocandins from Zalerion arboricola. II. Modification of product spectrum by mutation and medium manipulation. J. Antibiot. (1992) 45:1867-1874.
4. IWAMOTO T, FUJIE A, TSURUMI Y et al.: FR900403, a new antifungal antibiotic produced by a Kernia sp. J. Antibiot. (1990) 43:1183-1185.
5. CARVER PL: Micafungin. Ann. Pharmacother. (2004) 38:1707-1721.
6. HIGASHIYAMA Y, KOHNO S: Micafungin: a therapeutic review. Expert Rev. Anti. Infect. Ther. (2004) 2:345-355.
7. MERCK AND CO: Cancidas (caspofungin acetate for intravenous injection). prescribing information (2003).
8. WALSH TJ: Antifungal pharmacokinetics in children: when smaller may mean bigger. Proceedings of the 15th Annual Focus on Fungus. Miami, FL, USA (2005).
9. ODIO CM, ARAYA R, PINTO LE et al.: Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. (2004) 23:1093-1097.
10. BENJAMIN DK, DRISCOLL T, SEIBEL NL et al.: Safety and Pharmacokinetics of Anidulafungin in Pediatric Patients with Neutropenia. Proceedings of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004).
11. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
12. ODDS FC, MOTYL M, ANDRADE R et al.: Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. (2004) 42:3475-3482.
13. ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. (2003) 20:121-136.
14. DIEKEMA DJ, PETROELJE B, MESSER SA et al.: Activities of available and investigational antifungal agents against rhodotorula species. J. Clin. Microbiol. (2005) 43:476-478.
15. ZAAS AK, BOYCE M, SCHELL W et al.: Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J. Clin. Microbiol. (2003) 41:5233-5235.
16. VAN DUIN D, CASADEVALL A, NOSANCHUK JD: Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob. Agents Chemother. (2002) 46:3394-3400.
17. KURTZ MB, HEATH IB, MARRINAN J et al.: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480-1489.
18. ESPINEL-INGROFF A: Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. (2003) 41:403-409.
19. DOUGLAS CM, FOOR F, MARRINAN JA et al.: The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc. Natl. Acad. Sci. USA (1994) 91:12907-12911.
20. DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. (1997) 41:2471-2479.
21. OSHEROV N, MAY GS, ALBERT ND et al.: Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. (2002) 46:2462-2469.
22. SCHUETZER-MUEHLBAUER M, WILLINGER B, KRAPF G et al.: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol. (2003) 48:225-235.
23. MOUDGAL V, LITTLE T, BOIKOV D et al.: Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. (2005) 49:767-769.
24. HERNANDEZ S, LOPEZ-RIBOT JL, NAJVAR LK et al.: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. (2004) 48:1382-1383.
25. BECK-SAGUE C, JARVIS WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. (1993) 167:1247-1251.
26. HAJJEH RA, SOFAIR AN, HARRISON LH et al.: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. (2004) 42:1519-1527.
27. KAO AS, BRANDT ME, PRUITT WR et al.: The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. (1999) 29:1164-1170.
28. PAPPAS PG, REX JH, LEE J et al.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. (2003) 37:634-643.
29. GUDLAUGSSON O, GILLESPIE S, LEE K et al.: Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. (2003) 37:1172-1177.
30. RENTZ AM, HALPERN MT, BOWDEN R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. (1998) 27:781-788.
31. COLOMBO AL, NAKAGAWA Z, VALDETARO F et al.: Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals. Med. Mycol. (2003) 41:235-239.
32. PFALLER MA, DIEKEMA DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. (2004) 10(Suppl. 1):11-23.
33. KARTSONIS NA, SAAH A, LIPKA CJ et al.: Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J. Antimicrob. Chemother. (2004) 53:878-881.
34. KOHNO S, MASAOKA T, YAMAGUCHI H et al.: A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis. (2004) 36:372-379.
35. ANAISSIE E, OSTROSKY-ZEICHNER L, KONTOYLANNIS D et al.: Micafungin, an echinocandin antifungal agent for the treatment of new and refractory candidemia. Proceedings from the 13th Focus on Fungal Infections Meeting, Maui, HI, USA (2003).
36. KONTOYIANNIS D, BUELL DN, FRISBEE-HUME S et al.: Initial experience with FK463 for the treatment of candidemia in cancer patients. Proceedings from the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
37. KRAUSE DS, REINHARDT J, VAZQUEZ JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021-2024.
38. VILLANUEVA A, GOTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113:294-299.
39. KARTSONIS N, DINUBILE MJ, BARTIZAL K et al.: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir.Immune. Defic. Syndr. (2002) 31:183-187.
40. VILLANUEVA A, ARATHOON EG, GOTUZZO E et al.: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2001) 33:1529-1535.
41. ARATHOON EG, GOTUZZO E, NORIEGA LM et al.: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46:451-457.
42. DE WET N, LLANOS-CUENTAS A, SULEIMAN J et al.: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazoie for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. (2004) 39:842-849.
43. PETTENGELL K, MYNHARDT J, KLUYTS T et al.: Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther. (2004) 20:475-481.
44. KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) 39:770-775.
45. DAROUICHE RO: Echinocandins: ask not what they can do for esophageal candidiasis-ask what studies of esophageal candidiasis can do for them. Clin. Infect. Dis. (2004) 39:850-852.
46. WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. (2004) 351:1391-1402.
47. MATTIUZZI GN, KANTARJIAN H, ALVARDO G: Intravenous itraconazole (ITRA) versus caspofungin (CASPO) prophylaxis (P) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). Proceedings from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003)
48. VAN BURIK JA, RATANATHARATHORN V, STEPAN DE et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. (2004) 39:1407-1416.
49. MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39:1563-1571.
50. RATANATHARATHORN V, FLYNN P, VAN-BURIK JH et al.: Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. Proceedings from the 44th American Society of Hematology (ASH) Meeting. Philadelphia, PA, USA (2002).
51. PEREA S, GONZALEZ G, FOTHERGILL AW et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46:3039-3041.
52. PETRAITIS V, PETRAITIENE R, SARAFANDI AA et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. (2003) 187:1834-1843.
53. ARIKAN S, YURDAKUL P, HASCELIK G: Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob. Agents Chemother. (2003) 47:2640-2643.
54. DANNAOUI E, LORTHOLARY O, DROMER F: In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. (2004) 48:970-978.
55. HUBEL K, CHEMNITZ J, BROCHHAGEN HG et al.: Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int. J. Hematol. (2004) 79:289-292.
56. ALIFF TB, MASLAK PG, JURCIC JG et al.: Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer (2003) 97:1025-1032.
57. KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer (2003) 98:292-299.
58. MARR KA, BOECKH M, CARTER RA et al.: Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. (2004) 39:797-802.
59. FUJISA WA: Mycamine package insert (2005).
60. RAASCH RH: Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev. Anti. Infect. Ther. (2004) 2:499-508.
61. DOWELL JA, KNEBEL W, LUDDEN T et al.: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. (2004) 44:590-598.
62. OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. (2003) 47:3149-3154.
63. PFALLER MA, JONES RN, DOERN GV et al.: International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn. Microbiol. Infect. Dis. (1999) 35:19-25.
64. PFALLER MA, MESSER SA, MILLS K et al.: Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. (2001) 39:4387-4389.
65. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36:2950-2956.
66. KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) 39:770-775.
67. MARR KA, HACHEM R, PAPANICOLAOU G et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis. (2004) 6:110-116.
68. STOGNIEW M, DOWELL JA, KRAUSE D et al.: Population pharmacokinetics (PK) confirms absence of anidulafungin (ANID) drug-drug interactions. Program and Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic. (2004).
69. DOWELL JA, STOGNIEW M, KRAUSE D et al.: Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol. (2005) 45:227-233.